By writer to www.cancertherapyadvisor.com
Receipt of dialysis could also be a threat issue for inpatient mortality in sufferers with a number of myeloma (MM) being handled with high-dose melphalan and autologous stem cell transplantation (HDM-ASCT), in response to research outcomes printed within the European Journal of Haematology.
To judge inpatient mortality traits, investigators carried out a retrospective evaluation of hospital admissions for sufferers with MM and end-stage renal illness or continual kidney illness who have been handled with HDM-ASCT. Finish-stage renal illness required using dialysis, and continual kidney illness was outlined as having a creatinine clearance of beneath 60 mL/mm/1.73 m2 however with out the necessity for dialysis.
Affected person information used for evaluation have been from 2002 to 2014, and have been recognized via the Nationwide Inpatient Pattern database. Whereas the database accounted for roughly 20% of hospital discharges in america, weighted estimates allowed for extrapolation to hospitalizations throughout the nation.
The weighted estimate for inpatient admissions for HDM-ASCT amongst sufferers with MM was 47,253; the unweighted complete included 10,231 sufferers with MM. Of the weighted complete, solely 45 sufferers obtained peritoneal dialysis and 1709 obtained hemodialysis. Utilizing a weighted estimate, the investigators recognized 3020 sufferers with MM and continual kidney illness who underwent HDM-ASCT.
Presence of end-stage renal illness was independently related to an elevated threat of inpatient mortality (odds ratio [OR], 6.193; 95% CI, 3.585-10.701). Nonetheless, the chances of mortality weren’t vital for continual kidney illness (OR, 1.387; 95% CI, 0.757-2.539).
The inpatient mortality charge for sufferers receiving peritoneal dialysis was 20.5%. For sufferers given hemodialysis, the speed was 13.8%. Each of those mortality charges have been greater than for all the cohort of sufferers with MM, which was 1.1%; nevertheless, the distinction in inpatient mortality between these dialysis strategies was not vital (P =.58).
Inpatient mortality considerably decreased within the final 5 years of the research interval for sufferers with end-stage renal illness (15.6% in 2009 vs 5.0% in 2014; P <.001). The research investigators famous that this inpatient mortality charge was nonetheless elevated as compared with charges for sufferers on this research with out end-stage renal illness.
“The outcomes of our massive nationwide research reveal persistently excessive mortality charges in sufferers with MM on dialysis present process HDM-ASCT, even after accounting for different comorbidities,” concluded the investigators.
Disclosure: A few of the authors disclosed monetary relationships with pharmaceutical corporations and medical system producers. For a full listing of disclosures, please discuss with the unique research.
Mohyuddin GH, Abbasi S, Okoniewski M, et al. Inpatient mortality of patients with multiple myeloma with renal impairment undergoing autologous stem cell transplantation [published online July 14, 2020]. Eur J Haematol. doi: 10.1111/ejh.13487.
This text initially appeared on Hematology Advisor